A Phase 2, Open-Label, Multicentre Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, in Subjects With Refractory Generalized Myasthenia Gravis (KYSA-6)
Latest Information Update: 26 Mar 2025
At a glance
- Drugs KYV-101 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Myasthenia gravis
- Focus Adverse reactions; Therapeutic Use
- Acronyms KYSA-6
- Sponsors Kyverna Therapeutics
- 13 Jan 2025 According to a Kyverna therapeutics media release, the company expect to report interim Phase 2 data in the second half of 2025 and confirm registrational path with regulators 1H 2025.
- 20 Sep 2024 Study design presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
- 18 Sep 2024 According to a Kyverna therapeutics media release, case reports from three phase 3 clinical studies are to be presented at a company symposium titled, ''KYV-101 Unlocking the Potential of CAR T-cell Therapy in Neuroinflammatory Diseases'' to be held at 5:15 pm CET on Sep 18, 2024. The company and investigators will highlight case report experience from 11 patients from these studies.